Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 935 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: xrays Clear all
Withdrawn Not applicable Interventional

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

NCT03300401
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
Drug · Device · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation

NCT03110692
View directory record Official record
Conditions
Cancer
Interventions
Default initiation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

NCT04332419
View directory record Official record
Conditions
Hepatic Malignancies
Interventions
PET/CT, PET/MR, SIRT with Y-90
Device · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional

EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis

NCT03650712
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan
Diagnostic Test
Lead sponsor
Katie Larson Ode
Other
Eligibility
6 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Nuclear and Near-Infrared (NIR) Imaging in Melanoma

NCT01295931
View directory record Official record
Conditions
Melanoma
Interventions
Indocyanine Green (IC-Green), Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 23, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

NCT05641831
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, Chest Radiography, Echocardiography, Placebo Administration, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Miami, Florida • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Withdrawn Phase 2 Interventional

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

NCT06730100
View directory record Official record
Conditions
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

NCT02695628
View directory record Official record
Conditions
Adult Liver Carcinoma, Liver Cirrhosis
Interventions
18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography, Positron Emission Tomography
Drug · Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Novel Imaging Markers for Rheumatoid Arthritis

NCT01773681
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Magnetic Resonance Imaging (MRI), High-resolution peripheral quantitative computed tomography (HR-pQCT)
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 23, 2026, 5:06 AM EDT
Withdrawn Not applicable Interventional

FES-PET for Patients Treated on NCI Protocol 8762

NCT01714128
View directory record Official record
Conditions
Breast Cancer
Interventions
Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI

NCT03656250
View directory record Official record
Conditions
Nasopharyngeal Cancer
Interventions
PET/CT scans
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Intra-arterial Chemotherapy for Spinal Metastases

NCT01637766
View directory record Official record
Conditions
Spinal Diseases, Spinal Metastases, Spinal Tumors
Interventions
Melphalan (intra-arterial infusion)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 23, 2026, 5:06 AM EDT
Not yet recruiting Phase 1 Interventional

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

NCT06941480
View directory record Official record
Conditions
Neuroendocrine Tumor of the Lung, Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma of Prostate
Interventions
PET/CT, 177Lu-DTPA-SC16.56
Diagnostic Test · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy

NCT02155595
View directory record Official record
Conditions
Osteoporosis, Atypical Femoral Fractures, Prodromal Bone Deterioration
Interventions
500 without BP treatment, 500 with BP treatment
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
50 Years and older · Female only
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 23, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

NCT06357975
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

NCT03803475
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF )

NCT06965712
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Hospital Length of Stay
Interventions
Point-of-Care Ultrasound (POCUS)
Device
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

Artificial Intelligence (AI) for Proximal Caries Detection and Its Impact on Treatment Threshold

NCT07648212
View directory record Official record
Conditions
Caries,Dental
Interventions
Review of Radiograph Images
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Recruiting No phase listed Observational

REMS vs DXA for Osteoporosis Diagnosis and Fracture Risk Prediction

NCT07876882
View directory record Official record
Conditions
Osteoporosis Diagnosis, Bone Health, Fracture
Interventions
Not listed
Lead sponsor
BoneVue Diagnostics
Other
Eligibility
30 Years to 90 Years
Enrollment
250 participants
Timeline
2026 – 2027
U.S. locations
2
States / cities
Easton, Maryland • Salisbury, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

X-ray Fluoroscopy Fused With Computed Tomography (XFC) Technical Development

NCT00965679
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

NCT01926990
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
perfusion computed tomography
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 23, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Patient Specific Instruments Versus Standard Surgical Instruments

NCT01430468
View directory record Official record
Conditions
Total Shoulder Arthroplasty
Interventions
Glenoid Positioning System
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 23, 2026, 5:06 AM EDT
Active, not recruiting Early Phase 1 Interventional

An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

NCT05245786
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 5:06 AM EDT